does tirzepatide cause stomach pain vs. Semaglutide: What You Should Know Semaglutide and Tirzepatide Side Effects

The Evidence: Efficacy Beyond the Hype The first GLP-1 agonist, exenatide (Byetta, approved in 2005), required twice-daily injections and produced modest weight loss

It comes in immediate-release tablets, extended-release tablets, and liquid form

Early evidence suggests GLP-1 medications may also reduce neuroinflammation, which has been linked to disrupted sleep regulation in individuals with metabolic disease (ref, ref)

The survey inquired about participants perspectives on their eating behaviors before and after starting GLP-1 receptor agonists

Participants received once-weekly injections of retatrutide at either the 9mg or 12mg dose, or a placebo, over 68 weeks